Macrocyclic spiropyrrolidine derived antiviral agents
US11319325B1 · kind B1 · utility
10Cited by
53References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 20, 2021 |
| Grant date | May 3, 2022 |
| Priority date | — |
| Expiry date | Sep 20, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/20
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.